Using systems biology to evaluate targets and mechanism of action of drugs for diabetes comorbidities

Diabetologia

Volumn 59, Issue 12, 2016, Pages 2503-2506

  Mayer, Bernd ^a  

^a Emergentec Biodevelopment GmbH   (Austria)

Author keywords

Biomarker; Diabetic nephropathy; Molecular model; Network; Pharmacogenomics; Prediction; Review

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG TARGETING; HEALTH CARE PLANNING; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; ANIMAL; METABOLISM; PHARMACOGENETICS; PROCEDURES;

ANIMALS; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; PHARMACOGENETICS; SYSTEMS BIOLOGY;

EID: 84976864824     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4032-2     Document Type: Review

References (6)

1. Chan GC, Tang SC (2016) Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant 31:359–368
2. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
3. Schievink B, de Zeeuw D, Smink PA et al (2016) Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. Eur J Prev Cardiol 23:758–768
4. Pena MJ, Heinzel A, Heinze G et al (2015) A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. PLoS One 10:e0120995
5. Lambers Heerspink HJ, Oberbauer R, Perco P et al (2015) Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant 30:105–112
6. Cavallari LH, Mason DL (2016) Cardiovascular pharmacogenomics – implications for patients with CKD. Adv Chronic Kidney Dis 32:82–90